# AT101

Source: https://onco.cc/drugs/at101/  
OnCo record `at101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AT101 is an experimental CAR-T cell therapy from AbClon in phase 2 trials for hodgkin lymphoma, aimed at CD19.

## Summary

AT101 is a CAR-T cell therapy developed by AbClon. Its target is CD19 (the sponsor names CD19). The sponsor states: Autologous chimeric antigen receptor (CAR) T cells engineered to recognise CD19 on B-cell non-Hodgkin lymphoma cells. ClinicalTrials.gov describes the intervention as: Anti-CD19 Chimeric Antigen Receptor T cell. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT05338931, plans to enrol 82 participants with primary completion expected 2030-03-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: Autologous chimeric antigen receptor (CAR) T cells engineered to recognise CD19 on B-cell non-Hodgkin lymphoma cells.

## Sources

- ClinicalTrials.gov: trials of AT101: https://clinicaltrials.gov/search?intr=AT101

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [AbClon](https://onco.cc/companies/abclon/)
- trials: [Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma](https://onco.cc/trials/nct05338931/)

---
JSON: https://onco.cc/api/v1/entities/at101.json